ACADIA Pharmaceuticals Inc. (ACAD)
54.70 -1.16 (-2.07%)
After hours: 5:00PM EST
Chart Events
Performance Outlook
| Previous Close | 54.72 |
| Open | 54.89 |
| Bid | 54.49 x 800 |
| Ask | 56.15 x 2200 |
| Day's Range | 54.72 - 57.46 |
| 52 Week Range | 30.02 - 58.72 |
| Volume | 1,257,200 |
| Avg. Volume | 1,045,236 |
| Market Cap | 8.881B |
| Beta (5Y Monthly) | 1.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Simply Wall St.
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit
We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the...
- MarketWatch
These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden
The Pfizer (PFE)vaccine news does not take away the need for rapid testing, since it may be a year before vaccines are available to all risk groups notes Brian Weinstein, a health-care sector analyst at William Blair. Plus it’s not clear how many people will use the vaccine, because of safety concerns, says Deutsche Bank market strategist Marion Laboure. The good news is that Biden will likely preserve and expand the Affordable Care Act which is good for biopharma companies, notes Jefferies analyst Peter Welford.
- Zacks
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
